secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063701
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q3 net loss $50M; GLOW study shows tarcocimab 29-fold improvement
--------------------------------------------------------------------------------

- Net loss $50.0M ($0.95/shr) vs $77.0M ($1.47) in Q3 2022; cash $345.7M.
- R&D expenses fell to $36.2M from $61.7M due to development pause and forfeitures.
- GLOW phase 3: 41.1% tarcocimab patients had ≥2-step DRSS improvement vs 1.4% sham (p<0.0001).
- 89% risk reduction in sight-threatening complications; plan to reboot tarcocimab for single BLA.
- KSI-501 phase 1 enrollment complete; data expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023063701/0000950170-23-063701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023063701/kod-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer